Eileen Boyle, MD, PhD, NYU Langone, New York City, NY, outlines the clinical and genetic factors contributing to poorer outcomes and response to treatment in multiple myeloma, and discusses how the identification of high-risk subgroups might help to appropriately treat those patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть